Skip to main content
. Author manuscript; available in PMC: 2020 Mar 2.
Published in final edited form as: Int J Radiat Oncol Biol Phys. 2019 Aug 13;105(5):948–956. doi: 10.1016/j.ijrobp.2019.08.008

Table 4.

Multivariate analysis for factors associated with bPFS and TTNI by patient

Characteristic HR (95% CI) P value

bPFS
ADT 0.36 (0.19–0.67) .001
 HSPC 0.35 (0.18–0.69) .002
 Pre-RT PSA 1.01 (0.99–1.02) .48
 GTV 1.23 (1.02–1.45) .04
status
 M1 0.86 (0.33–2.25) .75
 Mx 1.08 (0.68–1.71) .74
 Nodal disease 1.34 (0.85–2.12) .21
 Treatment when de novo 0.56 (0.17–1.85) .34
TTNI
 GTV 1.20 (0.96–1.49) .11
 ADT 0.38 (0.18–0.78) .009
Site
 Node 1.44 (0.85–2.44) .17
 HSCP 0.40 (0.19–0.85) .02
 Pre-RT PSA 1.008 (0.99–1.03) .33
 T1/T2 0.69 (0.40–1.18) .17
M status
 M1 0.99 (0.33–2.92) .98
 Mx 0.85 (0.51–1.41) .52
 PSA-DT 0.84 (0.63–1.12) .24
 Treatment when de novo 0.41 (0.10–1.63) .21

Abbreviations: ADT = androgen deprivation therapy; bPFS = biochemical progression-free survival; CI = confidence interval; GTV = gross tumor volume; HR = ha=ard ratio; HSPC = hormone sensitive prostate cancer; OPC = oligometastatic prostate cancer; PSA = prostate specific antigen; PSA-DT = prostate specific antigen; RT = radiation therapy; TTNI = time to next intervention.